WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants 25 February 2021
Pfizer and BioNTech commence global clinical trial to evaluate COVID-19 vaccine in pregnant women 18 February 2021
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY® 04 January 2021
Pfizer and BioNTech to supply the U.S. with 100 million additional doses of COVID-19 vaccine 23 December 2020
Pfizer and BioNTech receive authorization in the European Union for COVID-19 vaccine 21 December 2020
Pfizer and BioNTech receive CHMP positive opinion for their COVID-19 vaccine 21 December 2020
Pfizer and BioNTech celebrate historic first authorization in the U.S. of vaccine to prevent COVID-19 14 December 2020
Pfizer and BioNTech receive FDA Advisory Committee vote supporting potential first Emergency Use Authorization for vaccine to combat COVID-19 in the U.S. 11 December 2020
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial of BNT162b2 COVID-19 vaccine candidate in The New England Journal of Medicine 10 December 2020
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to combat COVID-19 09 December 2020
Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19 02 December 2020
Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine 20 November 2020
Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints 18 November 2020
Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study 09 November 2020
BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2 06 October 2020
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial 14 September 2020
Pfizer and BioNTech announce data from preclinical studies of mRNA-based vaccine candidate against COVID-19 09 September 2020
Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19 21 August 2020
Pfizer announces agreement with Gilead to manufacture remdesivir for treatment of COVID-19 11 August 2020
Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate 31 July 2020
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.